Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin

Meet the New Group of Weight-Loss Drugs. The Industry Is Betting Big on Amylin

After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of weight-loss drugs called amylins is drawing the drug industry’s attention and dollars.
Read the article on Barrons >

Read More from the Global Wellness News ™